566 research outputs found
Supplementary_material – Supplemental material for Prevalence of treatment-resistant psychoses in the community: A naturalistic study
No full textSupplemental material, Supplementary_material for Prevalence of treatment-resistant psychoses in the community: A naturalistic study by Katherine Beck, Robert McCutcheon, Lucy Stephenson, Marcela Schilderman, Natasha Patel, Rosalind Ramsay and Oliver D Howes in Journal of Psychopharmacology</p
sj-docx-1-jop-10.1177_02698811231200881 – Supplemental material for Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies
No full textSupplemental material, sj-docx-1-jop-10.1177_02698811231200881 for Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies by Yuya Mizuno, Abhishekh Hulegar Ashok, Bhagyashree Bhaskar Bhat, Sameer Jauhar and Oliver D Howes in Journal of Psychopharmacology</p
Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models
No full textPeople with psychotic disorders show abnormalities in several organ systems in addition to the central nervous system (CNS); and this contributes to excess mortality. However, it is unclear how strong the evidence is for alterations in non-CNS systems at the onset of psychosis, how the alterations in non-CNS systems compare to those in the CNS, or how they relate to symptoms. Here, we consider these questions, and suggest potential models to account for findings. We conducted a systematic meta-review to summarize effect sizes for both CNS (focusing on brain structural, neurophysiological, and neurochemical parameters) and non-CNS dysfunction (focusing on immune, cardiometabolic, and hypothalamic-pituitary-adrenal (HPA) systems) in first-episode psychosis (FEP). Relevant meta-analyses were identified in a systematic search of Pubmed and the methodological quality of these was assessed using the AMSTAR checklist (A Measurement Tool to Assess Systematic Reviews). Case-control data were extracted from studies included in these meta-analyses. Random effects meta-analyses were re-run and effect size magnitudes for individual parameters were calculated, as were summary effect sizes for each CNS and non-CNS system. We also grouped studies to obtain overall effect sizes for non-CNS and CNS alterations. Robustness of data for non-CNS and CNS parameters was assessed using Rosenthal's fail-safe N. We next statistically compared summary effect size for overall CNSand overall non-CNS alterations, as well as for each organ system separately. We also examined how non-CNS alterations correlate CNS alterations, and with psychopathological symptoms. Case-control data were extracted for 165 studies comprising a total sample size of 13,440. For people with first episode psychosis compared with healthy controls, we observed alterations in immune parameters (summary effect size: g = 1.19), cardiometabolic parameters (g = 0.23); HPA parameters (g = 0.68); brain structure (g = 0.40); neurophysiology (g = 0.80); and neurochemistry (g = 0.43). Grouping non-CNS organ systems together provided an effect size for overall non-CNS alterations in patients compared with controls (g = 0.58), which was not significantly different from the overall CNS alterations effect size (g = 0.50). However, the summary effect size for immune alterations was significantly greater than that for brain structural (P < 0.001) and neurochemical alterations (P < 0.001), while the summary effect size for cardiometabolic alterations was significantly lower than neurochemical (P = 0.04), neurophysiological (P < 0.001), and brain structural alterations (P = 0.001). The summary effect size for HPA alterations was not significantly different from brain structural (P = 0.14), neurophysiological (P = 0.54), or neurochemical alterations (P = 0.22). These outcomes remained similar in antipsychotic naive sensitivity analyses. We found some, but limited and inconsistent, evidence that non-CNS alterations were associated with CNS changes and symptoms in first episode psychosis. Our findings indicate that there are robust alterations in non-CNS systems in psychosis, and that these are broadly similar in magnitude to a range of CNS alterations. We consider models that could account for these findings and discuss implications for future research and treatment
Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling study
No full textThe impact of the clinical high-risk for psychosis (CHR-P) construct is dependent on accurately predicting outcomes. Individuals with brief limited intermittent psychotic symptoms (BLIPS) have higher risk of developing a first episode of psychosis (FEP) compared to individuals with attenuated psychotic symptoms (APS). Supplementing subgroup stratification with information from candidate biomarkers based on neurobiological parameters, such as resting-state, regional cerebral blood flow (rCBF), may help refine risk estimates. Based on previous evidence, we hypothesized that individuals with BLIPS would exhibit increased rCBF compared to APS in key regions linked to dopaminergic pathways. Data from four studies were combined using ComBat (to account for between-study differences) to analyse rCBF in 150 age- and sex-matched subjects ( = 30 healthy controls [HCs], = 80 APS, = 20 BLIPS and = 20 FEP). Global gray matter (GM) rCBF was examined in addition to region-of-interest (ROI) analyses in bilateral/left/right frontal cortex, hippocampus and striatum. Group differences were assessed using general linear models: (i) alone; (ii) with global GM rCBF as a covariate; (iii) with global GM rCBF and smoking status as covariates. Significance was set at 0.05). All results were robust to addition of covariates ( > 0.05). No significant clusters were identified in whole-brain voxel-wise analyses ( > 0.05 ). Weak-to-moderate evidence was found for an absence of rCBF differences between APS and BLIPS in Bayesian ROI analyses. On this evidence, APS and BLIPS are unlikely to be neurobiologically distinct. Due to this and the weak-to-moderate evidence for the null hypothesis, future research should investigate larger samples of APS and BLIPS through collaboration across large-scale international consortia. [Abstract copyright: Copyright © 2023 Oliver, Davies, Zelaya, Selvaggi, De Micheli, Catalan, Baldwin, Arribas, Modinos, Crossley, Allen, Egerton, Jauhar, Howes, McGuire and Fusar-Poli.
sj-docx-1-jop-10.1177_02698811231177287 – Supplemental material for The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia
No full textSupplemental material, sj-docx-1-jop-10.1177_02698811231177287 for The histamine system and cognitive function: An in vivo H3 receptor PET imaging study in healthy volunteers and patients with schizophrenia by Atheeshaan Arumuham, Matthew M Nour, Mattia Veronese, Ellis Chika Onwordi, Eugenii A Rabiner and Oliver D Howes in Journal of Psychopharmacology</p
Consensus statement on the use of clozapine during the COVID-19 pandemic
No full textPublished online on April 3, 2020.
Psychopharmacology for the Clinician.
To be published in vol. 45, no. 4?Dan Siskind, William G. Honer, Scott Clark, Christoph U. Correll, Alkomiet Hasan, Oliver Howes, John M. Kane, Deanna L. Kelly, Robert Laitman, Jimmy Lee, James H. MacCabe, Nick Myles, Jimmi Nielsen, Peter F. Schulte, David Taylor, Helene Verdoux, Amanda Wheeler, Oliver Freudenreic
sj-docx-1-jop-10.1177_02698811221099643 – Supplemental material for The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls
No full textSupplemental material, sj-docx-1-jop-10.1177_02698811221099643 for The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls by Katherine Beck, Atheeshaan Arumuham, Stefan Brugger, Robert A McCutcheon, Mattia Veronese, Barbara Santangelo, Colm J McGinnity, Joel Dunn, Stephen Kaar, Nisha Singh, Toby Pillinger, Faith Borgan, Teresa Sementa, Radhouene Neji, Sameer Jauhar, Franklin Aigbirhio, Istvan Boros, Federico Turkheimer, Alexander Hammers, David Lythgoe, James Stone and Oliver D Howes in Journal of Psychopharmacology</p
sj-docx-1-jop-10.1177_02698811221122031 – Supplemental material for The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [<sup>18</sup>F]-FDOPA imaging in schizophrenia
No full textSupplemental material, sj-docx-1-jop-10.1177_02698811221122031 for The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia by Ilinca Angelescu, Stephen J Kaar, Tiago Reis Marques, Faith Borgan, Mattia Veronesse, Alice Sharman, Anil Sajjala, Bill Deakin, John Hutchison, Charles Large and Oliver D Howes in Journal of Psychopharmacology</p
sj-docx-1-jop-10.1177_02698811231171532 – Supplemental material for Low-frequency monitoring for community clozapine initiations: A comparative study relative to standard frequency assessments
No full textSupplemental material, sj-docx-1-jop-10.1177_02698811231171532 for Low-frequency monitoring for community clozapine initiations: A comparative study relative to standard frequency assessments by Yuya Mizuno, Devi L. Bridglal, Jack Coumbe, Hari McGrath, Ayush Adhikari, Emma Butler, Ilaria Bonoldi, David Taylor and Oliver D. Howes in Journal of Psychopharmacology</p
- …
